Natixis Advisors LLC Has $9.12 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Natixis Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 292,305 shares of the company’s stock after buying an additional 18,606 shares during the quarter. Natixis Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $9,123,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of TEVA. Global Retirement Partners LLC grew its holdings in Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares during the period. Banque Cantonale Vaudoise grew its position in shares of Teva Pharmaceutical Industries by 6.3% in the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after purchasing an additional 306 shares during the period. Ethic Inc. grew its position in shares of Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after purchasing an additional 325 shares during the period. Allworth Financial LP increased its stake in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $34.21 on Monday. The stock has a market capitalization of $39.34 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 3.49 and a beta of 0.84. The business has a 50-day moving average of $32.82 and a 200-day moving average of $31.68. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on TEVA. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Bank of America increased their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Finally, Truist Financial lifted their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares in the company, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christine Fox sold 21,258 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the sale, the executive vice president directly owned 63,647 shares in the company, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 421,470 shares of company stock worth $14,570,945. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported new real-world survey data showing AUSTEDO and AUSTEDO XR improved quality-of-life measures for Huntington’s disease chorea patients and reduced caregiver strain, supporting the outlook for one of its key branded medicines. Article Title
• Positive Sentiment: Teva expanded its European biosimilars business with the launch of AHZANTIVE, strengthening its growth strategy and broadening its presence in ophthalmology. Article Title
• Neutral Sentiment: Industry coverage highlighted Teva as a generic-drug stock to watch as biosimilars, complex generics and specialty drugs become increasingly important growth drivers. Article Title

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.